

해외 바이오의약품 임상 현황 (2021.3.1~2021.3.7)

한국바이오의약품협회, 2021.3.9.
출처: ClinicalTrials.gov

○ 미국 84건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04688658	Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma	Unresectable Melanoma	Drug: Nivolumab Drug: Duvelisib	John Kirkwood Secura Bio, Inc. Bristol-Myers Squibb University of Pittsburgh	Phase 1 Phase 2	
NCT04652908	Cellular Therapy for In Utero Repair of Myelomeningocele - The CuRe Trial	Myelomeningocele	Biological: Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix	Diana Lee Farmer California Institute for Regenerative Medicine (CIRM) University of California, Davis	Phase 1 Phase 2	
NCT04648046	CAR-T Cells for HIV Infection	HIV Infections	Drug: Cyclophosphamide Biological: LVgp120duoCAR-T cells, low dose Biological: LVgp120duoCAR-T cells, high dose Other: Analytic Treatment Interruption	Steven Deeks Caring Cross University of California, San Francisco	Phase 1 Phase 2	
NCT04639245	Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Metastatic Lung Non-Small Cell Carcinoma Metastatic Malignant Solid Neoplasm Metastatic Triple-Negative Breast Carcinoma Metastatic Urothelial Carcinoma Prognostic Stage IV Breast Cancer AJCC v8 Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8	Drug: Atezolizumab Drug: Cyclophosphamide Drug: Fludarabine Biological: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells Biological: PD1 Inhibitor	Fred Hutchinson Cancer Research Center SignalOne Bio, Inc.	Phase 1 Phase 2	
NCT04634357	ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma	Hepatoblastoma Hepatocellular Carcinoma (HC) Liver Neoplasms Metastatic Liver Cancer Liver Cancer HEMNOS	Drug: ET140203 T Cells	Eureka Therapeutics Inc.	Phase 1 Phase 2	
NCT04620603	Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer	Cutaneous Malignant Melanoma	Radiation: Low Dose Rate Brachytherapy (LDR) Drug: Nivolumab	Case Comprehensive Cancer Center	Phase 1 Phase 2	
NCT04517435	ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma	Diffuse Large B-Cell Lymphoma	Drug: ME-401 Drug: Rituximab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristine Drug: Prednisone	Deepa Jagadeesh Case Comprehensive Cancer Center	Phase 1 Phase 2	
NCT04441047	Universal Anti-Viral Vaccine for Healthy Elderly Adults	Virus Diseases	Drug: AlloStim	Immunovative Therapies, Ltd. Mirror Biologics, Inc.	Phase 1 Phase 2	
NCT04467723	Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC	NSCLC Stage IV NSCLC, Recurrent	Drug: Atezolizumab	University of Kansas Medical Center Parkview cancer institute	Phase 1 Phase 2	
NCT04263831	LOW DOSE IL-2 FOR THE TREATMENT OF CROHN'S DISEASE	Crohn Disease	Drug: Interleukin-2 (aldesleukin).	Boston Children's Hospital	Phase 1 Phase 2	
NCT03678467	Evaluation of EpiBone-CMF for Mandibular Ramus Reconstruction	Mandible Tumor Mandibular Injuries Mandible; Deformity	Combination Product: EB-CMF	EpiBone, Inc.	Phase 1 Phase 2	
NCT04784247	Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma	Advanced Sarcoma	Drug: Lenvatinib Drug: Pembrolizumab	Memorial Sloan Kettering Cancer Center Merck Sharp & Dohme Corp. Parker Institute for Cancer Immunotherapy	Phase 2	
NCT04776876	Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome	Advanced Neuroendocrine Neoplasm Carcinoid Syndrome	Biological: Retifanlimab Drug: Telotristat Ethyl	M.D. Anderson Cancer Center	Phase 2	
NCT04774419	Radiation and TSR-042 in People With Endometrial Cancer After They Receive Surgery	Endometrial Cancer	Radiation: Intensity modulated radiation therapy (IMRT) Drug: TSR-042	Memorial Sloan Kettering Cancer Center Tesaro, Inc.	Phase 2	
NCT04762901	LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer	Breast Cancer	Drug: Niraparib Drug: Doxorubicin Drug: Cyclophosphamide Drug: Paclitaxel Drug: Pegfilgrastim Drug: Carboplatin	Antoinette Tan, MD Tesaro, Inc. Atrium Health	Phase 1	
NCT04754321	Pembrolizumab and Radiation Therapy Before and During Surgery for the Treatment of Persistent or Recurrent Head and Neck Cancer	Head and Neck Carcinoma of Unknown Primary Locally Recurrent Head and Neck Squamous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Oral Cavity Squamous Cell Carcinoma Recurrent Pharyngeal Squamous Cell Carcinoma Resectable Head and Neck Squamous Cell Carcinoma	Radiation: External Beam Radiation Therapy Radiation: Intraoperative Radiation Therapy Biological: Pembrolizumab Other: Quality-of-Life Assessment Procedure: Salvage Surgery	Ohio State University Comprehensive Cancer Center	Phase 1	
NCT04739371	Food Intake and Intra-Nasal Insulin for African American Adults (FIINAAL)	Insulin	Drug: Insulin, Regular, Human Drug: Placebo	Pennington Biomedical Research Center Nutrition Obesity Research Center	Phase 1	
NCT04737161	Safety of T Regulatory Cell Therapy in Subjects With COVID-19 Induced Acute Respiratory Distress Syndrome	Acute Respiratory Distress Syndrome Covid19	Biological: T regulatory cells	Stanford University	Phase 1	
NCT04736966	Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease	Alcoholic Liver Disease	Drug: Guselkumab 30mg Drug: Guselkumab 70mg Drug: Guselkumab 100mg	University of California, San Diego	Phase 1	
NCT04735471	A Study of ADI-001 in B Cell Malignancies	Lymphoma, Follicular Lymphoma, Mantle-Cell Marginal Zone Lymphoma Lymphoma, Burkitt Mediastinal Lymphoma Diffuse Large B Cell Lymphoma Lymphoma, Non-Hodgkin Lymphoma, Large B-Cell, Diffuse	Genetic: ADI-001 Drug: Fludarabine Drug: Cyclophosphamide Drug: Bendamustine Drug: Interleukin-2	Adicet Bio, Inc	Phase 1	
NCT04728698	Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells for COVID-19-Induced Acute Respiratory Distress	Covid19 ARDS	Drug: COVI-MSC Drug: Placebo	Sorrento Therapeutics, Inc.	Phase 2	
NCT04708886	Romosozumab in Women With Chronic SCI	Osteoporosis Bone Loss Osteopenia, Osteoporosis Spinal Cord Injuries Chronic Spinal Paralysis	Drug: Romosozumab Drug: Alendronate	Northwestern University Amgen	Phase 2	
NCT04696731	Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma	Advanced/Metastatic Clear Cell Renal Cell Carcinoma	Genetic: ALLO-316 Biological: ALLO-647 Drug: Fludarabine Drug: Cyclophosphamide	Allogene Therapeutics	Phase 1	
NCT04684979	Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies	B-Cell Lymphoid Malignancies Hematologic Malignancy Non-Hodgkin Lymphoma	Biological: Hematopoietic Stem Cells from HLA-compatible Related Biological: Hematopoietic Stem Cells from HLA Unrelated	Baptist Health South Florida	Phase 2	
NCT04634825	Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer	Head and Neck Cancer Head and Neck Neoplasms Head and Neck Squamous Cell Carcinoma	Biological: Enoblituzumab Biological: Retifanlimab Biological: Tebotelimab	MacroGenics	Phase 2	
NCT04608812	Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection	Glioma, Malignant High Grade Glioma Glioblastoma Glioblastoma Multiforme Anaplastic Astrocytoma	Drug: OS2966 Drug: Gadoteridol Device: Infuseon Cleveland Multiport Catheter	OncoSynergy, Inc. Infuseon Therapeutics, Inc.	Phase 1	
NCT04585490	Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC	Non Small Cell Lung Cancer NSCLC, Stage III NscL	Drug: Durvalumab Drug: Carboplatin Drug: Pemetrexed Drug: Paclitaxel Drug: Cisplatin Device: AVENIO ctDNA Surveillance Kit	Stanford University AstraZeneca	Phase 3	
NCT04585477	Adjuvant Durvalumab for Early Stage NSCLC Patients With ctDNA Minimal Residual Disease	Non-small Cell Lung Cancer Non-small Cell Lung Cancer Stage II Non-small Cell Lung Cancer Stage III Non-small Cell Lung Cancer Stage III	Device: AVENIO ctDNA Surveillance Kit Drug: Durvalumab	Stanford University AstraZeneca	Phase 2	
NCT04572815	Ustekinumab for the Prevention of Acute Graft Versus Host Disease After Unrelated Donor Hematopoietic Cell Transplant	Hematologic and Lymphocytic Disorder Hematopoietic and Lymphoid Cell Neoplasm	Drug: Placebo Administration Other: Quality-of-Life Assessment Other: Questionnaire Administration Biological: Ustekinumab	Fred Hutchinson Cancer Research Center Food and Drug Administration (FDA)	Phase 2	
NCT04569461	Trimodality Approach to Localized Prostate Cancer: Pembrolizumab, ADT, and SBRT Followed by Prostatectomy	Prostate Cancer	Drug: pembrolizumab Radiation: Stereotactic body radiation therapy Drug: Short-term androgen deprivation therapy Procedure: Radical Prostatectomy	Bridget Koo Merck Sharp & Dohme Corp. Duke University	Phase 2	
NCT04512287	PRP for Treatment of Peyronie's Disease	Peyronie Disease Sexual Dysfunction, Physiological Sexual Dysfunction Male Genital Diseases, Male	Drug: Autologous Platelet Rich Plasma Other: Saline Solution	University of Miami	Phase 2	
NCT04477759	Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer	Head and Neck Neoplasm	Radiation: 50 Gy Radiation Therapy Radiation: 55 Gy Radiation Therapy Radiation: 60 Gy Radiation Therapy Drug: Atezolizumab	Medical College of Wisconsin Genentech, Inc.	Phase 1	
NCT04474847	Abatacept for the Treatment of Giant Cell Arteritis	Giant Cell Arteritis	Drug: Abatacept Drug: Placebo	University of Pennsylvania	Phase 3	
NCT04466618	Endogenous GLP-1 Secretion on Islet Function in People With and Without Type 2 Diabetes	Healthy Type 2 Diabetes	Biological: Saline Biological: Exendin-9-39 Biological: Saline + Intralipid Heparin Biological: Exendin-9-39 + Intralipid Heparin	Adrian Vella National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Mayo Clinic	Phase 3	
NCT04466475	Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma	CD38 Positive Plasma Cell Myeloma	Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Melphalan Procedure: Peripheral Blood Stem Cell Transplantation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) National Institutes of Health (NIH)	Phase 1	
NCT04465643	Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor	Nerve Sheath Tumors	Drug: Nivolumab Drug: Ipilimumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bristol-Myers Squibb	Phase 1	
NCT04444622	Immunotherapy for Third Line Metastatic Colorectal Cancer	Metastatic Colorectal Cancer	Biological: AlloStim	Immunovative Therapies, Ltd. Mirror Biologics, Inc.	Phase 2	
NCT04303572	The Hemophilia Inhibitor Eradication Trial	Hemophilia A With Inhibitor	Drug: Eclotacti Drug: Emicizumab	Margaret Ragni Health Resources and Services Administration (HRSA) University of Pittsburgh	Phase 3	
NCT04303559	The Hemophilia Inhibitor Prevention Trial	Hemophilia A Without Inhibitor	Drug: Eclotact Injectable Product Drug: Emicizumab Injection (Hemlibra)	Margaret Ragni Health Resources and Services Administration (HRSA) University of Pittsburgh	Phase 3	
NCT04301778	Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma	Unresectable Intrahepatic Cholangiocarcinoma	Drug: Durvalumab Drug: SNDX-6532	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Syndax Pharmaceuticals AstraZeneca	Phase 2	

해외 바이오의약품 임상 현황 (2021.3.1~2021.3.7)

한국바이오의약품협회, 2021.3.9.
출처: ClinicalTrials.gov

NCT04274166	Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum	Pyoderma Gangrenosum	Drug: secukinumab 150 mg (2 injections per dose)	Wake Forest University Health Sciences Novartis	Phase 2
NCT04230031	Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma	Multiple Myeloma	Drug: Daratumumab	Saad Z. Usmani, MD Janssen Research & Development, LLC Atrium Health	Phase 2
NCT04190056	Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer	Anatomic Stage IV Breast Cancer AJCC v8 Prognostic Stage IV Breast Cancer AJCC v8	Biological: Pembrolizumab Drug: Tamoxifen Drug: Vorinostat	University of California, San Francisco Merck Sharp & Dohme Corp.	Phase 2
NCT04171622	Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer	Metastatic Thyroid Gland Carcinoma Poorly Differentiated Thyroid Gland Carcinoma Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 Thyroid Gland Squamous Cell Carcinoma Unresectable Thyroid Gland Carcinoma	Drug: Lenvatinib Biological: Pembrolizumab	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2
NCT04056910	Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors	Advanced Solid Tumor IDH1 Mutation Glioma	Drug: ivosidenib and nivolumab	Jason J. Luke, MD Agios Pharmaceuticals, Inc. Bristol-Myers Squibb University of Pittsburgh	Phase 2
NCT03939585	Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT	Allogeneic Stem Cell Transplant Candidate Acute Myeloid/Lymphoblastic Leukemia Myelodysplastic Syndrome Myeloproliferative Neoplasms Lymphoproliferative Disorders	Biological: Cellular therapy product	Case Comprehensive Cancer Center	Phase 1
NCT03760575	Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)	Mesothelioma Pleural	Drug: Pembrolizumab Procedure: Indocyanine Green (ICG) Image-Guided Surgery Drug: Cisplatin Drug: Pemetrexed	Abramson Cancer Center of the University of Pennsylvania	Phase 1
NCT03735277	Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke	Acute Ischemic Stroke	Biological: HPC, Cord Blood	BHI Therapeutic Sciences	Phase 1
NCT03617445	Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients	Clostridium Difficile Infection Recurrence	Drug: FMT oral capsule Drug: Oral Vancomycin Drug: FMT oral placebo Drug: Oral Vancomycin placebo	University of Wisconsin, Madison	Phase 2
NCT03527108	Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC	Non Small Cell Lung Cancer	Drug: Nivolumab Drug: Ramucirumab	Fox Chase Cancer Center Bristol-Myers Squibb Eli Lilly and Company	Phase 2
NCT03508479	Study of Airway Inflammatory Responses to Experimental Rhinovirus Infection	Healthy Volunteers Rhinovirus	Biological: RG-HRV16	University of North Carolina, Chapel Hill Environmental Protection Agency (EPA)	Phase 1
NCT03463239	Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora	Urologic Diseases Male Urogenital Diseases Penile Diseases Corpus Callosum Malformation Corpora Caverosa; Inflammation Trauma Injury	Biological: Autologous tissue engineered corpora	Wake Forest University Health Sciences United States Department of Defense	Phase 1
NCT03258558	Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures	Urologic Diseases Male Urogenital Diseases Urethral Stricture Urethral Injury	Biological: Autologous Engineered Urethral Construct	Wake Forest University Health Sciences United States Department of Defense	Phase 1
NCT04741074	Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy	CKD Diabetic Kidney Disease Type 2 Diabetes Mellitus in Obese Obesity Severe Obesity	Drug: Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution Drug: Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution	Geisinger Clinic	Phase 3
NCT04678830	COVID-19 Long-Haulers Study	Coronavirus Disease 2019	Drug: Placebo Drug: Leronlimab (700mg)	CytoDyn, Inc Amarex Clinical Research	Phase 2
NCT04594031	US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease	Sickle Cell Disease Umbilical Cord Blood Hematopoietic Cell Proliferation	Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)	ExCellThera inc California Institute for Regenerative Medicine (CIRM)	Phase 1
NCT04486378	A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer	Colorectal Cancer Stage II Colorectal Cancer Stage III	Drug: RO7198457 intravenous (i.v.) Other: Observational group (no intervention)	BioNTech SE	Phase 2
NCT04344860	Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial	Von Willebrand Diseases Postpartum Hemorrhage	Drug: Recombinant Von Willebrand factor Drug: Tranexamic Acid Injection (Cyklokapron)	Margaret Ragni University of Pittsburgh	Phase 3
NCT03980769	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders	Benign Neoplasm	Drug: Thiotepa Drug: Treosulfan Drug: Fludarabine Phosphate Biological: Rabbit Anti-Thymocyte Globulin Procedure: Allogeneic Hematopoietic Stem Cell Transplantation	Fred Hutchinson Cancer Research Center National Cancer Institute (NCI) National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI)	Phase 2
NCT03690011	Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells	T-cell Acute Lymphoblastic Leukemia T-cell Acute Lymphoblastic Lymphoma T-non-Hodgkin Lymphoma	Genetic: CD7.CAR/28zeta CAR T cells Drug: Fludarabine Drug: Cytosan	Baylor College of Medicine The Methodist Hospital System Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1
NCT04273269	A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis	GM1 Gangliosidosis	Genetic: LYS-GM101	LYSGENE	Phase 1 Phase 2
NCT04761198	A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.	Solid Tumor, Adult Advanced Solid Tumor Metastatic Solid Tumor	Drug: Etigilimab dosing Drug: Nivolumab	Mereo BioPharma CON Clinical Research	Phase 1 Phase 2
NCT04658472	Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)	Chronic Inflammatory Demyelinating Polyradiculoneuropathy	Drug: BIVV020	Sanofi	Phase 2
NCT04584255	Niraparib + TSR042 In BRCA Mutated Breast Cancer	Stage I Breast Cancer Stage II Breast Cancer Stage III Breast Cancer Breast Cancer HER2-negative Breast Cancer Germline BRCA1 Gene Mutation Germline BRCA2 Gene Mutation	Drug: Niraparib Drug: Dostarlimab	Dana-Farber Cancer Institute Translational Breast Cancer Research Consortium Johns Hopkins University GlaxoSmithKline	Phase 2
NCT04575922	Nivolumab+Ipilimumab+RT in MSS mCRC	Metastatic Microsatellite Stable Colorectal Cancer	Drug: Nivolumab Drug: Ipilimumab Radiation: Radiation Therapy	Massachusetts General Hospital Bristol-Myers Squibb	Phase 2
NCT04148352	Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy	Allergies Food Milk	Drug: Dupilumab Other: Placebo	Andrew J Long, PharmD Stanford University	Phase 2
NCT04673617	AB-101 as Monotherapy and In Combination With Rituximab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma	Non Hodgkin Lymphoma	Drug: AB-101 Drug: Rituximab Drug: Interleukin-2 Drug: Cyclophosphamide Drug: Fludarabine	Artiva Biotherapeutics, Inc.	Phase 1 Phase 2
NCT04614103	Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer	Metastatic Non Small Cell Lung Cancer	Biological: LN-145	Iovance Biotherapeutics, Inc.	Phase 2
NCT04557384	A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer	Advanced Solid Tumor	Drug: Ramucirumab	Eli Lilly and Company	Phase 1
NCT04717375	Study of BND-22 in Participants With Advanced Solid Tumors	Cancer	Drug: BND-22	Biond Biologics	Phase 1 Phase 2
NCT04747431	A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)	Frontotemporal Dementia	Drug: PBFT02	Passage Bio, Inc.	Phase 1 Phase 2
NCT04770532	A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin	Diabetes Mellitus, Type 2	Drug: Insulin degludec Drug: Insulin Icodec	Novo Nordisk A/S	Phase 3
NCT04761822	COVID-19: SARS Vaccination	SARS-CoV Infection COVID-19 Allergic Reaction Mast Cell Disorder Non-atopic	Biological: Moderna COVID-19 Vaccine Biological: Pfizer-BioNTech COVID-19 Vaccine Biological: Placebo	National Institute of Allergy and Infectious Diseases (NIAD) Immune Tolerance Network (ITN) Rho Federal Systems Division, Inc.	Phase 2
NCT04760626	A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before	Diabetes Mellitus, Type 2	Drug: Insulin icodec Drug: Insulin Glargine 100U/mL Drug: Insulin Degludec Drug: Insulin Glargine 300U/mL	Novo Nordisk A/S	Phase 3
NCT04740931	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion	Macular Edema Central Retinal Vein Occlusion Hemiretinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04740905	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion	Macular Edema Branch Retinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2

해외 바이오의약품 임상 현황 (2021.3.1~2021.3.7)

한국바이오의약품협회, 2021.3.9.
출처: ClinicalTrials.gov

NCT04665843	A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck	Squamous Cell Carcinoma of Head and Neck	Drug: Atezolizumab Drug: Tiragolumab Drug: Placebo	Hoffmann-La Roche	Phase 2	
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	
NCT04772989	A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies	Advanced Solid Tumor NSCLC Melanoma Cervical Cancer Multiple Myeloma Lymphoma, Non-Hodgkin DLBCL Gastric Cancer Gastroesophageal Junction Adenocarcinoma Esophageal Cancer	Drug: AB308 Drug: Zimberelimab	Arcus Biosciences, Inc.	Phase 1	
NCT04062708	CHIO3 Trial: Chemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer	Stage IIIA Non-small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer	Drug: Durvalumab Procedure: Surgery Radiation: Radiotherapy	Alliance Foundation Trials, LLC AstraZeneca	Phase 2	
NCT04775082	SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity	Obesity	Drug: Liraglutide Drug: Placebo	Novo Nordisk A/S	Phase 3	
NCT04489537	Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B	Hemophilia A With Inhibitor Hemophilia B With Inhibitor	Biological: MarzAA	Catalyst Biosciences	Phase 3	
NCT04636268	FIB Grifols Congenital Deficiency for On-demand Treatment and Surgical Prophylaxis	Congenital Afibrinogenemia Hypofibrinogenemia	Biological: FIB Grifols	Instituto Grifols, S.A. Grifols Therapeutics LLC	Phase 3	

○ 영국 11건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	URL
NCT04768842	A Study of Two Different Formulations of LY3209590 in Healthy Participants	Healthy	Drug: LY3209590	Eli Lilly and Company	Phase 1	
NCT04285827	Safety of Single Ascending Doses of CSL889 in Adult Patients With Stable Sickle Cell Disease	Sickle Cell Disease	Biological: CSL889	CSL Behring	Phase 1	
NCT04273269	A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis	GM1 Gangliosidosis	Genetic: LYS-GM101	LYSOGENE	Phase 1 Phase 2	
NCT04758767	CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma	Multiple Myeloma	Drug: CID-103	CASI Pharmaceuticals, Inc.	Phase 1	
NCT04740931	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion	Macular Edema Central Retinal Vein Occlusion Hemiretinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	
NCT04740905	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion	Macular Edema Branch Retinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	
NCT04665843	A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck	Squamous Cell Carcinoma of Head and Neck	Drug: Atezolizumab Drug: Tiragolumab Drug: Placebo	Hoffmann-La Roche	Phase 2	
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	
NCT04489537	Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B	Hemophilia A With Inhibitor Hemophilia B With Inhibitor	Biological: MarzAA	Catalyst Biosciences	Phase 3	
NCT04747431	A Study of P8FT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)	Frontotemporal Dementia	Drug: P8FT02	Passage Bio, Inc.	Phase 1 Phase 2	

○ 프랑스 13건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	URL
NCT04656184	A Randomized Phase III Multicenter Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIg) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment	Kawasaki Disease	Drug: ANAKINRA Drug: Intravenous immunoglobulin	Assistance Publique - Hôpitaux de Paris Sobi	Phase 3	
NCT04274023	Study on TSR-042 in Advanced Clear Cell Sarcoma	Sarcoma, Clear Cell	Drug: TSR-042	Italian Sarcoma Group GlaxoSmithKline	Phase 2	
NCT04758767	CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple Myeloma	Multiple Myeloma	Drug: CID-103	CASI Pharmaceuticals, Inc.	Phase 1	
NCT04730544	Identification of the Optimal Combination Dosing Schedule of Nivolumab and Ipilimumab in Patients With dMMR and/or MSI Metastatic Colorectal Cancer: A GERCOR Open-label, Randomized, Non-comparative, Two-stage Phase II Trial	Colorectal Cancer Metastatic MSI-H Colorectal Cancer	Drug: Nivolumab Drug: Ipilimumab	GERCOR - Multidisciplinary Oncology Cooperative Group Bristol-Myers Squibb	Phase 2	
NCT04713514	OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC	Platinum-sensitive Ovarian Cancer Relapsed Ovarian Cancer	Drug: OSE2101 Drug: Pembrolizumab 25 MG/ML [Keytruda]	ARCAGY/ GINECO GROUP OSE Immunotherapeutics Merck Sharp & Dohme Corp.	Phase 2	
NCT04703686	Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy	Diffuse Large B-Cell Lymphoma Refractory Refractory Indolent Adult Non-Hodgkin Lymphoma Refractory Transformed B-cell Non-Hodgkin Lymphoma Refractory Primary Mediastinal Large B-Cell Cell Lymphoma Refractory Mantle Cell Lymphoma	Drug: Obinituzumab Drug: RO7082859	The Lymphoma Academic Research Organisation	Phase 2	
NCT04602377	Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHT	Small Cell Ovarian Carcinoma	Drug: Pembrolizumab 25 MG/ML [Keytruda]	ARCAGY/ GINECO GROUP Merck Sharp & Dohme Corp.	Phase 2	
NCT04629833	Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy	Steroid-refractory Acute Graft-versus-host Disease	Biological: MC0518 Biological: BAT	medac GmbH	Phase 3	
NCT03915678	Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors	Solid Tumor, Adult Pancreatic Cancer Virus-associated Tumors Non Small Cell Lung Cancer Melanoma Bladder Cancer Triple Negative Breast Cancer	Drug: Association atezolizumab + BDB001 + RT Drug: Association atezolizumab + BDB001 + RT	Institut Bergonié Roche Pharma AG National Cancer Institute, France Seven and Eight Biopharmaceuticals Inc	Phase 2	
NCT04665843	A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck	Squamous Cell Carcinoma of Head and Neck	Drug: Atezolizumab Drug: Tiragolumab Drug: Placebo	Hoffmann-La Roche	Phase 2	
NCT04740931	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion	Macular Edema Central Retinal Vein Occlusion Hemiretinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	
NCT04740905	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion	Macular Edema Branch Retinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	

○ 독일 8건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	URL
NCT04770272	Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy	Triple-negative Breast Cancer	Drug: Atezolizumab 840 MG in 14 ML Injection Drug: Atezolizumab 1200 MG in 20 ML Injection Drug: Carboplatin Drug: Paclitaxel Drug: Epirubicin Drug: Cyclophosphamide Procedure: Biopsy Arm A Procedure: Biopsy Arm B Procedure: Surgery	Palleos Healthcare GmbH Roche Pharma AG Phaon Scientific GmbH University Hospital, Essen University Hospital Erlangen	Phase 2	
NCT04672395	A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19	COVID-19	Biological: CpG 1018/Alum- adjuvanted SCB-2019 vaccine Biological: Placebo; 0.9% saline	Clover Biopharmaceuticals AUS Pty Ltd Coalition for Epidemic Preparedness Innovations International Vaccine Institute	Phase 2 Phase 3	

해외 바이오의약품 임상 현황 (2021.3.1~2021.3.7)

한국바이오의약품협회, 2021.3.9.
출처: ClinicalTrials.gov

NCT04629833	Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy	Steroid-refractory Acute Graft-versus-host Disease	Biological: MC0518 Biological: BAT	medac GmbH	Phase 3	
NCT04770532	A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin	Diabetes Mellitus, Type 2	Drug: Insulin degludec Drug: Insulin Icodec	Novo Nordisk A/S	Phase 3	
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	
NCT04740931	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion	Macular Edema Central Retinal Vein Occlusion Hemiretinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	
NCT04740905	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion	Macular Edema Branch Retinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	

○ 중국 27건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	유지 URL
NCT04785027	Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis	Traditional Chinese Medicine Drug Effect Drug Safety Psoriasis Mesenchymal Stromal Cells	Drug: PSORI-CM01 formula Drug: Gu Ben Hua Yu formula Biological: adipose-derived multipotent mesenchymal stem cells	Guangdong Provincial Hospital of Traditional Chinese Medicine	Phase 1 Phase 2	
NCT04781413	Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer	Stage IIIC Gastric Cancer	Drug: Nab-PTX, Sintilimab, S-1	Ruijin Hospital	Phase 1 Phase 2	
NCT04775680	Study of ADG106 in Combination With PD-1 Antibody in Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma	Solid Tumor Non Hodgkin Lymphoma	Biological: ADG106 injection Biological: PD-1 antibody injection	Adagene (Suzhou) Limited Adagene Inc	Phase 1 Phase 2	
NCT04765462	Allogeneic y8 T Cell Therapy for Treatment of Patients With Advanced Solid Cancers	Advanced Solid Tumour	Biological: Allogeneic y8 T cells	Chinese PLA General Hospital	Phase 1 Phase 2	
NCT04762485	Humanized CD7 CAR T-cell Therapy for r/r CD7+ Acute Leukemia	T Lymphoblastic Leukemia/Lymphoma Mixed Phenotype Acute Leukemia Acute Myeloid Leukemia	Biological: Humanized CD7 CAR-T cells	The First Affiliated Hospital of Soochow University PersonGen BioTherapeutics (Suzhou) Co., Ltd.	Phase 1 Phase 2	
NCT04205435	β-globin Restored Autologous HSC in β-thalassemia Major Patients	β-thalassemia Major	Biological: β-globin restored autologous HSC	Bioray Laboratories PLA 923 Hospital	Phase 1 Phase 2	
NCT04787211	A Phase 2 Safety and Efficacy Study of Human Monoclonal Antibodies, BR11-196 and BR11-198 Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) Versus Gardasil9 in Healthy Females 18-26 Years of Age	COVID-19	Drug: BR11-196 and BR11-198 Drug: Placebo	Brii Biosciences Limited TSB Therapeutics (Beijing) CO.LTD	Phase 2	
NCT04782895	Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) Versus Gardasil9 in Healthy Females 18-26 Years of Age	Cervical Cancer Condylomata Acuminata	Biological: Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58) Vaccine(E.Coli) Biological: Gardasil9	Xiamen University Xiamen Innovax Biotech Co., Ltd Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.	Phase 3	
NCT04781686	Apatinib Plus Carrizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer	Metastatic Gastric Adenocarcinoma Metastatic Gastroesophageal Junction Adenocarcinoma	Drug: Carrizumab Drug: Apatinib Mesylate Drug: S1 Drug: Docetaxel injection	Zhou Fuxiang Hubei Cancer Hospital Henan Provincial People's Hospital Huangshi Central Hospital Zhongnan Hospital	Phase 2	
NCT04777162	Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer	Gastric Cancer Colo-rectal Cancer	Drug: Tislelizumab Drug: Anlotinib	Peking University	Phase 2	
NCT04767295	A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Advanced Esophageal Squamous Cell Carcinoma (ESCC)	Esophageal Squamous Cell Carcinoma	Drug: Camrelizumab, Albumin Paclitaxel, Carboplatin	Hunan Cancer Hospital Jiangsu Hengrui Medicine Co., Ltd.	Phase 2	
NCT04766840	Donor-derived CAR-T Cells in the Treatment of AML Patients	AML	Drug: CAR-T cells	Beijing Immunochina Medical Science & Technology Co., Ltd.	Phase 1	
NCT04745221	Efficacy and Safety of Auto-FMT in Preventing aGVHD	Graft Versus Host Disease, Acute	Other: autologous fecal bacteria	The First Affiliated Hospital of Soochow University	Phase 1	
NCT04733963	Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer	Colorectal Cancer	Drug: Fruquintinib Plus Capecitabine Drug: Bevacizumab Plus Capecitabine	Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2	
NCT04725448	Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma	Pulmonary Sarcomatoid Carcinoma Non-small Cell Lung Cancer Lung Diseases Thoracic Neoplasms	Drug: Toripalimab Drug: Bevacizumab Drug: Nab-paclitaxel Drug: Carboplatin	Sichuan Cancer Hospital and Research Institute	Phase 2	
NCT04711343	Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects	Psoriasis	Drug: BAT2306 Drug: Cosentyx (US-licensed) Drug: Cosentyx (EU-licensed)	Bio-Thera Solutions	Phase 1	
NCT04665609	Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC	Hepatocellular Carcinoma Thermal Ablation Anlotinib PDL-1	Drug: Anlotinib and TQB2450 solution Drug: TQB2450 solution	Chinese PLA General Hospital	Phase 3	
NCT04649476	Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma	Oral Squamous Cell Carcinoma	Drug: Camrelizumab Drug: Camrelizumab plus TPF	Hospital of Stomatology, Wuhan University Jiangsu Hengrui Medicine Co., Ltd.	Phase 2	
NCT04417166	Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma	Lymphoma, Extranodal NK-T-Cell	Drug: Pembrolizumab Radiation: Involved Field Radiation Therapy	International Extranodal Lymphoma Study Group (IELSG)	Phase 2	
NCT03271515	Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL	Leukemia Lymphoma	Biological: anti-CD19 anti-CD20 Bispecific CAR-T	Beijing Doing Biomedical Co., Ltd.	Phase 1	
NCT04777084	The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.	Non-Small Cell Lung Cancer	Drug: IBI318	Hunan Province Tumor Hospital	Phase 2	
NCT04712643	A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma	Hepatocellular Carcinoma	Drug: Atezolizumab Drug: Bevacizumab Device: Transarterial chemoembolization (TACE)	Hoffmann-La Roche	Phase 3	
NCT04778956	Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma	Nasopharyngeal Carcinoma PD-1 Surgery	Drug: Toripalimab Procedure: salvage surgery	Sun Yat-sen University First Affiliated Hospital, Sun Yat-Sen University Nanfeng Hospital of Southern Medical University First People's Hospital of Foshan Zhongshan People's Hospital, Guangdong, China Tenth Affiliated Hospital, Sun Yat-sen University	Phase 3	
NCT04743739	Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of IMN	Idiopathic Membranous Nephropathy	Drug: Rituximab Drug: cyclosporine	Peking Union Medical College Hospital Beijing Tongren Hospital Chinese Academy of Medical Sciences, Fuwai Hospital The Luhe Teaching Hospital of the Capital Medical University The Seventh Affiliated Hospital, Sun Yat-sen University First Affiliated Hospital of Xinjiang Medical University Nanyang Nanshi Hospital of Henan University Shanghai Fosun Pharmaceutical Development Co, Ltd.	Phase 3	
NCT02546739	Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL	Leukemia Lymphoma	Biological: Anti-CD19-CAR	Beijing Doing Biomedical Co., Ltd. The First Hospital of Jilin University Hebei Yanda Ludaopei Hospital	Phase 1	
NCT04740931	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion	Macular Edema Central Retinal Vein Occlusion Hemiretinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	

해외 바이오의약품 임상 현황 (2021.3.1~2021.3.7)

한국바이오의약품협회, 2021.3.9.
출처: ClinicalTrials.gov

NCT04740905	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion	Macular Edema Branch Retinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	---
-------------	--	---	---	---	---------	-----

○ 일본 7건

NCT Number	Title	Conditions	Interventions	Sponsor/Collaborators	Phases	URL
NCT04557384	A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer	Advanced Solid Tumor	Drug: Ramucirumab	Eli Lilly and Company	Phase 1	---
NCT04740931	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion	Macular Edema Central Retinal Vein Occlusion Hemiretinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	---
NCT04740905	A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion	Macular Edema Branch Retinal Vein Occlusion	Drug: Faricimab Drug: Aflibercept Procedure: Sham Procedure	Hoffmann-La Roche Chugai Pharmaceutical	Phase 3	---
NCT04770532	A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Degludec, in People With Type 2 Diabetes Who Use Daily Insulin	Diabetes Mellitus, Type 2	Drug: Insulin degludec Drug: Insulin Icodec	Novo Nordisk A/S	Phase 3	---
NCT04712643	A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Hepatocellular Carcinoma	Hepatocellular Carcinoma	Drug: Atezolizumab Drug: Bevacizumab Device: Transarterial chemoembolization (TACE)	Hoffmann-La Roche	Phase 3	---
NCT04677179	A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: LY3471851 Drug: Placebo	Eli Lilly and Company	Phase 2	---
NCT04630028	A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)	Colitis, Ulcerative	Drug: Ustekinumab Dose Based on BSA and Body Weight Drug: Matching Placebo	Janssen Research & Development, LLC	Phase 3	---